Federal Register / Vol. 62, No. 207 / Monday, October 27, 1997 / Notices 55645

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than November 21,

1997.

A. Federal Reserve Bank of Cleveland

(Jeffery Hirsch, Banking Supervisor)

1455 East Sixth Street, Cleveland, Ohio

44101-2566:

1. Strasburg Bancorp, Inc., Strasburg,

Ohio; to become a bank holding

company by acquiring 100 percent of

the voting shares of Strasburg Savings,

Strasburg, Ohio (in formation).

B. Federal Reserve Bank of San

Francisco (Pat Marshall, Manager of

Analytical Support, Consumer

Regulation Group) 101 Market Street,

San Francisco, California 94105-1579:

1. Timberland Bancorp, Inc.,

Hoquiam, Washington; to become a

bank holding company by acquiring 100

percent of the voting shares of

Timberland Savings Bank, SSB,

Hoquiam, Washington.

Board of Governors of the Federal Reserve

System, October 22, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–28423 Filed 10–24–97; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies;

Correction

This notice corrects a notice (FR Doc.

97-27636) published on pages 54460 -

54461 of the issue for Monday, October

20, 1997.

Under the Federal Reserve Bank of

Richmond heading, the entry for

NationsBank Corporation, and NB

Holdings Corporation, both of Charlotte,

North Carolina, is revised to read as

follows:

A. Federal Reserve Bank of

Richmond (A. Linwood Gill III,

Assistant Vice President) 701 East Byrd

Street, Richmond, Virginia 23261-4528:

1. NationsBank Corporation, and NB

Holdings Corporation, both of Charlotte,

North Carolina; to merge with Barnett

Banks, Inc., Jacksonville, Florida, and

thereby indirectly acquire Barnett Bank,

National Association, Jacksonville,

Florida, and Community Bank of the

Islands, Sanibel, Florida.

In connection with this application,

Applicants also have applied to acquire

First of America Bank - Florida, FSB,

Tampa, Florida, and thereby engage in

traditional thrift activities, pursuant to §

225.28(b)(4) of the Board’s Regulation Y;

Barnett Community Development

Corporation, Jacksonville, Florida, and

thereby engage in investing in

corporations or projects designed

primarily to promote community

welfare, pursuant to § 225.28(b)(12) of

the Board’s Regulation Y; EquiCredit

Corporation, Jacksonville, Florida, and

its direct and indirect subsidiaries, and

thereby engage in the activities of

originating home equity and purchase

money loans, acquiring such loans

originated from third parties, and

securitizing such loans in the secondary

market, pursuant to § 225.28(b)(1) of the

Board’s Regulation Y, and in acting as

principal, agent, or broker for credit

related insurance, pursuant to §

225.28(b)(11) of the Board’s Regulation

Y; Equity/Protect Reinsurance

Company, Jacksonville, Florida, and

thereby engage in the activities of

reinsuring credit related insurance

policies sold to EquiCredit Corporation

customers, pursuant to § 225.28(b)(11)

of the Board’s Regulation Y; and Honor

Technologies, Inc., Maitland, Florida,

and thereby engage in operating an

electronic funds transfer network and in

data processing and management

consulting activities, pursuant to §§

225.28(b)(9) and (b)(14), respectively of

the Board’s Regulation Y.

In connection with this proposal,

NationsBank has applied to acquire an

option for 19.9 percent of Barnett’s

outstanding shares. Barnett also has

applied to acquire an option for 10

percent of the shares of NationsBank

Corporation and all of its bank and

nonbanking subsidiaries. These options

will expire upon consummation of the

merger.

Comments on this application must

be received by November 13, 1997.

Board of Governors of the Federal Reserve

System, October 22, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–28424 Filed 10–24–97; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97D–0420]

Guidance for Industry on OTC

Treatment of Hypercholesterolemia;

Availability

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

availability of a guidance document

entitled ‘‘OTC Treatment of

Hypercholesterolemia.’’ The guidance is

intended to clarify the agency’s current

thinking on the treatment of

hypercholesterolemia using over-thecounter (OTC) drug products. The

agency’s Center for Drug Evaluation and

Research (CDER) believes that drugs for

the treatment of hypercholesterolemia

should not be sold OTC in the United

States.

DATES: Written comments may be

submitted at any time.

ADDRESSES: Submit written requests for

single copies of the guidance ‘‘OTC

Treatment of Hypercholesterolemia’’ to

the Drug Information Branch (HFD–

210), Center for Drug Evaluation and

Research, Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857. Send one selfaddressed adhesive label to assist that

office in processing your requests.

Submit written comments on the

guidance to the Dockets Management

Branch (HFA–305), Food and Drug

Administration, 12420 Parklawn Dr.,

rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:

Michael Weintraub, Center for Drug

Evaluation and Research (HFD–105),

Food and Drug Administration, 5600
55646 Federal Register / Vol. 62, No. 207 / Monday, October 27, 1997 / Notices

Fishers Lane, Rockville, MD 20857,

301–827–2250.

SUPPLEMENTARY INFORMATION: FDA is

announcing the availability of a

guidance for industry entitled ‘‘OTC

Treatment of Hypercholesterolemia.’’

Several sponsors have recently

expressed interest in marketing

cholesterol-lowering agents as OTC drug

products. These requests have raised

several regulatory policy and medical

therapy issues.

This guidance document represents

the agency’s current thinking on OTC

treatment of hypercholesterolemia. It

does not create or confer any rights for

or on any person and does not operate

to bind FDA or the public. An

alternative approach may be used if

such an approach satisfies the

requirement of the applicable statute,

regulations, or both.

Interested persons may, at any time,

submit written comments on the

guidance to the Dockets Management

Branch (address above). Two copies of

any comments are to be submitted,

except that individuals may submit one

copy. Comments are to be identified

with the docket number found in

brackets in the heading of this

document. The guidance and received

comments are available for public

examination in the Dockets

Management Branch between 9 a.m. and

4 p.m., Monday through Friday. Persons

with access to the Internet may obtain

the guidance by using the World Wide

Web (WWW). For WWW access, go to

‘‘http://www.fda.gov/cder/guidance/

index.htm’’.

Dated: October 17, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–28298 Filed 10–24–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment

Request; Treatment Observation’s

Study

SUMMARY: In compliance with Section

3506(c)(2)(A) of the Paperwork

Reduction Act of 1995, for opportunity

for public comment on proposed data

collection projects, the National

Institute on Alcohol Abuse and

Alcoholism (NIAAA), National

Institutes of Health (NIH) will publish

periodic summaries of proposed

projects to be submitted to the Office of

Management and Budget (OMB) for

review and approval.

PROPOSED COLLECTION: The Treatment

Research Branch (TRB), intends to

conduct the study for ‘‘Treatment

Observation’’. The TRB is authorized by

Section 452 of Part G of Title IV of the

Public Health Service Act (42 U.S.C.

288) as amended by the NIH

Revitalization Act of 1993 (Pub. L. 103–

43).

The information proposed for

collection will be used by the NIAAA to

observe group treatment at up to 20

treatment facilities. At each facility,

directors will be asked to provide

information about treatment practices

and about the client population. At each

facility at least seven members of the

treatment staff will be asked to provide

information about their treatment

activities, personal experiences and

training. At each facility eight treatment

groups will be observed. The group

leader will be asked to complete a

questionnaire about the observed

session and other client demographics.

At least seven group members will also

be asked to complete a questionnaire

about the observed group session. The

target population for the study is a

group of outpatient public and private

providers that will include group

treatment as part of their overall plan of

clinical therapeutics.

The specific aim of this study is the

testing of instruments and

methodologies for the systematic

measurement of the content, process,

and context of group treatment.

The annual burden estimates are as

follows:

Type and number of respondents

Responses

per

respondent

Total

responses Hours Total hours

Facility Director—20 ....................................................................................... 1 20 .75 15

Group Leader—160 ........................................................................................ 1 160 .334 55

Treatment Staff—140 ..................................................................................... 1 140 .334 48

Group Member—1120 .................................................................................... 1 1120 .334 381

Total Number of Respondents ................................................................ ........................ 1440

Total Number of Responses ................................................................... ........................ 1440 .......................... ........................

Total Hours .............................................................................................. ........................ 499 .......................... ........................

REQUEST FOR COMMENTS: Comments are

invited on: (a) Whether the proposed

collection is necessary, including

whether the information has practical

use; (b) ways to enhance the clarity,

quality, and use of the information to be

collected; (c) the accuracy of the agency

estimate of burden of the proposed

collection; and (d) ways to minimize the

collection burden of the respondents.

Send written comments to Dr. Margaret

Mattson, Treatment Research Branch,

Division of Clinical and Prevention

Research (DCPR), NIAAA. NIH, Willco

Building 6000, Room 505, 6000

Executive Boulevard, Bethesda,

Maryland 20892–7003.

FOR FURTHER INFORMATION CONTACT:

To request more information on the

proposed project or to obtain a copy of

the data collection plans, contact Dr.

Margaret Mattson, Treatment Research

Branch, Division of Clinical and

Prevention Research (DCPR), NIAAA,

NIH, 6000 Willco Building, Room 505,

6000 Executive Boulevard, Bethesda,

Maryland 20892–7003, or call non-tollfree number (301) 443–0638.

COMMENTS DUE DATE: Comments

regarding this information collection are

best assured of having their full effect if

received within 60-days of the date of

this publication.

Dated: October 20, 1997.

Martin K. Trusty,

Executive Officer, NIAAA.

[FR Doc. 97–28382 Filed 10–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice